770 related articles for article (PubMed ID: 26076215)
1. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Freund KB; Korobelnik JF; Devenyi R; Framme C; Galic J; Herbert E; Hoerauf H; Lanzetta P; Michels S; Mitchell P; Monés J; Regillo C; Tadayoni R; Talks J; Wolf S
Retina; 2015 Aug; 35(8):1489-506. PubMed ID: 26076215
[TBL] [Abstract][Full Text] [Related]
2. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
3. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
4. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
5. [Management of aflibercept in routine clinical practice].
Cabrera López F
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
7. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
10. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials in Branch Retinal Vein Occlusion.
Panakanti TK; Chhablani J
Middle East Afr J Ophthalmol; 2016; 23(1):38-43. PubMed ID: 26957837
[TBL] [Abstract][Full Text] [Related]
12. Changes in Retinal Microvasculature and Visual Acuity After Antivascular Endothelial Growth Factor Therapy in Retinal Vein Occlusion.
Winegarner A; Wakabayashi T; Fukushima Y; Sato T; Hara-Ueno C; Busch C; Nishiyama I; Shiraki N; Sayanagi K; Nishida K; Sakaguchi H; Nishida K
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2708-2716. PubMed ID: 29860457
[TBL] [Abstract][Full Text] [Related]
13. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
14. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
[TBL] [Abstract][Full Text] [Related]
16. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
18. [Switching the Treatment Regime from PRN (pro re nata, as needed) to T&E (Treat and Extend) for Intravitreal Therapy with Anti-VEGF Agents in Private Practice or Small Institutions].
Imesch P; Sarra GM
Klin Monbl Augenheilkd; 2018 Jan; 235(1):39-46. PubMed ID: 27960220
[TBL] [Abstract][Full Text] [Related]
19. Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors.
Guichard MM; Xavier AR; Türksever C; Pruente C; Hatz K
Ophthalmic Res; 2018; 60(1):29-37. PubMed ID: 29566387
[TBL] [Abstract][Full Text] [Related]
20. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
